Mode
Text Size
Log in / Sign up
Phase 2 N=116 Randomized Double-blind Supportive Care

Effect of Steroids on Post-tonsillectomy Morbidities

Postoperative Pain · Postoperative Nausea and Vomiting

Enrolled (actual)
116
Serious AEs
0.0%
Results posted
Jul 2015
Primary outcome: Primary: Maximum Severity of Post-operative Pain — 37; 26; 13; 21 participants — p=0.033

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
IV dexamethasone (Drug); Oral prednisolone (Drug); Paracetamol (Drug); IV saline (Drug)
Age
Pediatric, Adult · 5+ yrs
Sex
All
Sponsor
King Fahd General Hospital
Primary completion
Mar 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Severity of Post-operative Pain
37; 26; 13; 21; 0; 3 0.033 sig
PRIMARY
Duration of Post-operative Pain
36; 23; 11; 19; 3; 8 0.026 sig
PRIMARY
Occurence of Post-operative Nausea
17; 29; 33; 21 0.016 sig
PRIMARY
Onset of Post-operative Nausea
33; 21; 10; 8; 4; 11 0.019 sig
PRIMARY
Duration of Post-operative Nausea
33; 21; 3; 8; 14; 15 0.012 sig
PRIMARY
Occurence of Postoperative Vomiting
25; 36; 25; 14 0.024 sig
PRIMARY
Total Number of Post-operative Vomiting Episodes
25; 14; 13; 9; 7; 19 0.02 sig
SECONDARY
Onset of 1st Post-operative Oral Intake
46; 37; 4; 13 0.017 sig
SECONDARY
Average Amount of Meal Per Day
16; 27; 34; 23 0.026 sig
SECONDARY
Average Frequency of Meals Per Day
2; 1; 20; 34; 28; 15 0.019 sig

Summary

This study aims to evaluate the effect of postoperative systemic rapid onset and short acting dexamethasone followed by a tapering dose of oral prednisolone on post-tonsillectomy morbidities. Half of the patients who comply with the inclusion criteria were selected to receive a single postoperative dose of intravenous dexamethasone followed by oral steroids; the second group received placebo.

Eligibility Criteria

Inclusion Criteria

  • Patients in the waiting list for tonsillectomy under general anesthesia who accepted to participate in the study.

Exclusion Criteria

  • Patients who are allergic to steroids or those who have medical conditions which contraindicate the use of steroid i.e diabetes mellitus, gastritis, or hypertension and those who were on exogenous steroid supplements.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02401529). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search